Post by Deleted on May 25, 2017 4:39:53 GMT
Gemphire Therapeutics has gained my interest over the past 3 months. Their lead product, gemcabene, has some serious potential in the dyslipidemia and possible NASH markets. News is expected on one of their phase 2 trials (HoFH) in June. The company has a low float, but their product has been studied pretty extensively. I think the real test will be in Q3 for a phase 2 trial with HeFH/ASCVD. If successful, gemcabene has a good chance to enter the market to rival Repatha/Praluent but in pill form. In terms of NASH, preliminary evidence supports activity in this space. However, I am a little skeptical for the NASH indication. The science is a little shaky in my opinion. On the other hand, a successful phase 2 in NASH would be icing on the cake (starts 2H 2017, readout 2H 2018).
Link to investor presentation found here: ir.gemphire.com/phoenix.zhtml?c=254241&p=irol-presentations
Link to investor presentation found here: ir.gemphire.com/phoenix.zhtml?c=254241&p=irol-presentations
